Beam Therapeutics Inc.
Beam Therapeutics Inc. (BEAM) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · BEAM · as of Sep 30, 2025
Ownership Breakdown
234
Institutional Holders
▲ 2 vs Q2
$2.59B
Total Inst. Value
▲ $742.63M vs Q2
102.88M
Shares Outstanding
freeFloat 91.13%
106.58M
13F Shares Held
▼ 1.80M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
BEAM largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC biological products, (no diagnostic substances) | 11.69M | 11.46% | 11.46% | $283.79B | Nov 13, 2025 | ▼ 1.27M |
ARK INVESTMENT MANAGEMENT LLC biological products, (no diagnostic substances) | 11.04M | 10.82% | 10.82% | $267.91B | Nov 12, 2025 | ▲ 2.19M |
FARALLON CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 10.06M | 9.87% | 9.87% | $244.23B | Feb 17, 2026 | ▲ 50.0K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 9.25M | 9.07% | 9.07% | $224.52B | Nov 7, 2025 | ▼ 455.4K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 8.15M | 7.99% | 7.99% | $197.76B | Nov 12, 2025 | ▲ 145.5K |
SUMITOMO MITSUI TRUST HOLDINGS, INC. biological products, (no diagnostic substances) | 4.83M | 4.74% | 4.74% | $117.24B | Oct 27, 2025 | ▲ 101.3K |
NIKKO ASSET MANAGEMENT AMERICAS, INC. biological products, (no diagnostic substances) | 4.83M | 4.74% | 4.74% | $117.24B | Nov 12, 2025 | ▲ 103.9K |
ARCH VENTURE MANAGEMENT, LLC biological products, (no diagnostic substances) | 4.54M | 4.45% | 4.45% | $110.19B | Nov 14, 2025 | — held |
STATE STREET CORP biological products, (no diagnostic substances) | 4.01M | 3.93% | 3.93% | $97.29B | Nov 14, 2025 | ▲ 370.4K |
BELLEVUE GROUP AG biological products, (no diagnostic substances) | 2.89M | 2.83% | 2.83% | $70.12B | Nov 14, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
26
Increased
+6.94M shares2
New Positions
first time holders18
Decreased
−4.55M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.39M
+6.94M / −4.55M
Net new holders
+10
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
BEAM insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
1
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Shaw Christi director | Jun 3, 2026 | Award | 19,676 | $29.55 | $581.4K | 19.7K | Form 4 ↗ |
Walsh Kathleen E director | Jun 3, 2026 | Award | 19,676 | $29.55 | $581.4K | 19.7K | Form 4 ↗ |
MARAGANORE JOHN director | Jun 3, 2026 | Award | 19,676 | $29.55 | $581.4K | 19.7K | Form 4 ↗ |
Fishman Mark director | Jun 3, 2026 | Award | 19,676 | $29.55 | $581.4K | 19.7K | Form 4 ↗ |
Guindo Chirfi director | Jun 3, 2026 | Award | 19,676 | $29.55 | $581.4K | 19.7K | Form 4 ↗ |
COOPER GRAHAM K director | Jun 3, 2026 | Award | 19,676 | $29.55 | $581.4K | 19.7K | Form 4 ↗ |
Evans John M. CEO | Apr 1, 2026 | Sale | 30,078 | $24.58 | $739.3K | 1.05M | Form 4 ↗ |
Simon Amy Chief Medical Officer | Apr 1, 2026 | Sale | 6,700 | $24.58 | $164.7K | 102.7K | Form 4 ↗ |
Cavanagh Bethany J SVP, Finance and Treasurer | Apr 1, 2026 | Sale | 3,242 | $24.58 | $79.7K | 51.2K | Form 4 ↗ |
Bellon Christine Chief Legal Officer | Apr 1, 2026 | Sale | 5,956 | $24.58 | $146.4K | 109.7K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Beam Therapeutics Inc. (BEAM) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 8.87%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Beam Therapeutics Inc. is FMR LLC, holding approximately 11.69 million shares — equal to 11.46% of outstanding shares — as of September 30, 2025.
A total of 234 institutional investors currently hold BEAM stock, with a combined institutional value of approximately $2.59 billion as of the most recent 13F filing period.
Frequently asked questions
BEAM ownershipBeam Therapeutics Inc. (BEAM) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is FMR LLC with a 11.46% stake. Company insiders hold 8.87%. Data sourced from SEC Form 13F as of September 30, 2025.